<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01873248</url>
  </required_header>
  <id_info>
    <org_study_id>DOTATATE12-001920</org_study_id>
    <nct_id>NCT01873248</nct_id>
  </id_info>
  <brief_title>Investigation of 68Ga-DOTATATE, as a PET Imaging Agent in Neuroendocrine Tumor Patients</brief_title>
  <official_title>Investigation of 68Ga-DOTATATE, as a PET Imaging Agent in Neuroendocrine Tumor Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jonsson Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jonsson Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, Phase 1-2, single center study in a total of 100 subjects with
      Neuroendocrine Tumors (NETs). Study participants will receive a one-time administration of
      68Ga-DOTATATE and undergo a PET/CT imaging study, to investigate its suitability as a PET
      imaging agent for NETs.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, we propose to use a well-established PET isotope, 68-Gallium (68Ga), bound to
      a somatostatin analogue, DOTA-octreotate, or DOTATATE, which has high affinity for the
      somatostatin receptor type 2 (SSTR2). Most gastro-entero-pancreatic (GEP) NETs express SSTR2
      on their cell surfaces; when the radiolabeled SSTR2 analogue binds to these receptors, the
      radioactive molecule is internalized and transported to the tumor cell nucleus, thus
      concentrating the radioactivity and improving the signal-to-noise ratio on the PET scan,
      particularly as the background rapidly clears. This internalization, combined with the
      improved physical principles of PET imaging, shorter half-life of the 68Ga (68 minutes vs.
      about three days for 111In), improved radiation dosimetry, faster scanning, and lower cost
      results in a greatly improved scan for diagnosis, staging and restaging of NET disease
      compared to conventional 111In-octreotide imaging. Additionally, 68Ga-DOTATATE PET/CT
      scanning can be performed in 1.5 hours from injection of the radiopharmaceutical to
      completion of the scan, vs. 2-3 days for 111In-octreotide imaging.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 26, 2013</start_date>
  <completion_date type="Anticipated">May 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measure the number of adverse events in patients receiving Ga68-DOTATATE PET</measure>
    <time_frame>3 years</time_frame>
    <description>We'll assess the safety and tolerability of Ga68-DOTATATE PET</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of lesions detected by 68GA-DOTATATE compared to conventional imaging techniques</measure>
    <time_frame>3 Years</time_frame>
    <description>We want to determine if the 68Ga-DOTATATE PET scan changes care plans compared to conventional imaging/diagnostic techniques (Octreoscan, MRI, CT).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Neuroendocrine Carcinoma</condition>
  <arm_group>
    <arm_group_label>Diagnostics with PET</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>68Ga-DOTATATE PET scans will be performed on subjects</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>68Ga-DOTATATE</intervention_name>
    <description>68Ga-DOTATATE will be given in tracer doses and injected intravenously to image Neuroendocrine tumors by Positron Emission Tomography.</description>
    <arm_group_label>Diagnostics with PET</arm_group_label>
    <other_name>68Ga-DOTATATE PET/CT scan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Known diagnosis of NET, suspected SSTR positive tumors or suspected NET recurrence.

          -  At least 18 years of age.

          -  Patient or patient's legally acceptable representative cognitively provides written
             informed consent.

          -  Able to provide informed consent.

          -  Females of childbearing potential must have a negative pregnancy test at
             screening/baseline.

        Exclusion Criteria:

          -  Use of any other investigational product or device within 30 days prior to dosing, or
             known requirement for any other investigational agent prior to completion of all
             scheduled study assessments.

          -  Patients with a body weight of 400 pounds or more or not able to enter the bore of the
             PET/CT scanner due to BMI, because of the compromise in image quality with CT, PET/CT
             and MRI that will result.

          -  Inability to lie still for the entire imaging time.

          -  Inability to complete the needed investigational and standard-of-care imaging
             examinations due to other reasons (severe claustrophobia, radiation phobia, etc.)

          -  Recognized concurrent active infection.

          -  Any additional medical condition, serious intercurrent illness, or other extenuating
             circumstance that, in the opinion of the Investigator, may significantly interfere
             with study compliance.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johannes Czernin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Johannes Czernin, MD</last_name>
    <phone>310-206-3226</phone>
    <email>JCzernin@mednet.ucla.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California Los Angeles, Nuclear Medicine Clinic of the Department of Molecular and Medical Pharmacology</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Johannes Czernin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Martin Auerbach, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.pet.ucla.edu</url>
    <description>Ahmanson Imaging Division</description>
  </link>
  <link>
    <url>http://www.pharmacology.ucla.edu</url>
    <description>Department of Molecular and Medical Pharmacology UCLA</description>
  </link>
  <reference>
    <citation>Modlin IM, Moss SF, Chung DC, Jensen RT, Snyderwine E. Priorities for improving the management of gastroenteropancreatic neuroendocrine tumors. J Natl Cancer Inst. 2008 Sep 17;100(18):1282-9. doi: 10.1093/jnci/djn275. Epub 2008 Sep 9.</citation>
    <PMID>18780869</PMID>
  </reference>
  <reference>
    <citation>Modlin IM, Oberg K, Chung DC, Jensen RT, de Herder WW, Thakker RV, Caplin M, Delle Fave G, Kaltsas GA, Krenning EP, Moss SF, Nilsson O, Rindi G, Salazar R, Ruszniewski P, Sundin A. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol. 2008 Jan;9(1):61-72. doi: 10.1016/S1470-2045(07)70410-2. Review.</citation>
    <PMID>18177818</PMID>
  </reference>
  <reference>
    <citation>Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A, Evans DB. One hundred years after &quot;carcinoid&quot;: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008 Jun 20;26(18):3063-72. doi: 10.1200/JCO.2007.15.4377. Review.</citation>
    <PMID>18565894</PMID>
  </reference>
  <reference>
    <citation>Rensing BJ, Hermans WR, Strauss BH, Serruys PW. Regional differences in elastic recoil after percutaneous transluminal coronary angioplasty: a quantitative angiographic study. J Am Coll Cardiol. 1991 May;17(6 Suppl B):34B-38B.</citation>
    <PMID>2016480</PMID>
  </reference>
  <reference>
    <citation>Virgolini I, Ambrosini V, Bomanji JB, Baum RP, Fanti S, Gabriel M, Papathanasiou ND, Pepe G, Oyen W, De Cristoforo C, Chiti A. Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE. Eur J Nucl Med Mol Imaging. 2010 Oct;37(10):2004-10. doi: 10.1007/s00259-010-1512-3.</citation>
    <PMID>20596866</PMID>
  </reference>
  <reference>
    <citation>Kowalski J, Henze M, Schuhmacher J, Mäcke HR, Hofmann M, Haberkorn U. Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D Phe(1)-Tyr(3)-Octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors. Mol Imaging Biol. 2003 Jan-Feb;5(1):42-8.</citation>
    <PMID>14499161</PMID>
  </reference>
  <reference>
    <citation>Hofmann M, Maecke H, Börner R, Weckesser E, Schöffski P, Oei L, Schumacher J, Henze M, Heppeler A, Meyer J, Knapp H. Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data. Eur J Nucl Med. 2001 Dec;28(12):1751-7. Epub 2001 Oct 31.</citation>
    <PMID>11734911</PMID>
  </reference>
  <reference>
    <citation>Gabriel M, Decristoforo C, Kendler D, Dobrozemsky G, Heute D, Uprimny C, Kovacs P, Von Guggenberg E, Bale R, Virgolini IJ. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med. 2007 Apr;48(4):508-18.</citation>
    <PMID>17401086</PMID>
  </reference>
  <reference>
    <citation>Putzer D, Gabriel M, Henninger B, Kendler D, Uprimny C, Dobrozemsky G, Decristoforo C, Bale RJ, Jaschke W, Virgolini IJ. Bone metastases in patients with neuroendocrine tumor: 68Ga-DOTA-Tyr3-octreotide PET in comparison to CT and bone scintigraphy. J Nucl Med. 2009 Aug;50(8):1214-21. doi: 10.2967/jnumed.108.060236. Epub 2009 Jul 17.</citation>
    <PMID>19617343</PMID>
  </reference>
  <reference>
    <citation>Prasad V, Ambrosini V, Hommann M, Hoersch D, Fanti S, Baum RP. Detection of unknown primary neuroendocrine tumours (CUP-NET) using (68)Ga-DOTA-NOC receptor PET/CT. Eur J Nucl Med Mol Imaging. 2010 Jan;37(1):67-77. doi: 10.1007/s00259-009-1205-y.</citation>
    <PMID>19618183</PMID>
  </reference>
  <reference>
    <citation>Ambrosini V, Tomassetti P, Franchi R, Fanti S. Imaging of NETs with PET radiopharmaceuticals. Q J Nucl Med Mol Imaging. 2010 Feb;54(1):16-23. Review.</citation>
    <PMID>20168283</PMID>
  </reference>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 3, 2013</study_first_submitted>
  <study_first_submitted_qc>June 5, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 10, 2013</study_first_posted>
  <last_update_submitted>June 12, 2017</last_update_submitted>
  <last_update_submitted_qc>June 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neuroendocrine Carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroendocrine Tumors</mesh_term>
    <mesh_term>Carcinoma, Neuroendocrine</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

